Journals / Genel Tıp Dergisi / 2013 / Cilt: 23 - Sayı: 4

Multiple drug resistance in glioblastoma

Glioblastoma tümörlerinde çoklu ilaç direnci

Pages
133–143
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the possible drug resistance mechanisms in glioblastoma were described in the light of recent literature by using systemic and integrative perspective

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In cellular perspective, neuronal and glial paradigms are two prevailing approaches for understanding both structure/function and pathology of central nervous system.
📊
Key Findings & Data:Moreover, activation of oncogenes and abnormalities of expression of Bcl-2 protein family members are mediating players in the development of drug resistance in glioblastoma.
💡
Conclusion & Impact:In this review, the possible drug resistance mechanisms in glioblastoma were described in the light of recent literature by using systemic and integrative perspective
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In cellular perspective, neuronal and glial paradigms are two prevailing approaches for understanding both structure/function and pathology of central nervous system. Neuronal paradigm explains brain pathology mainly based on neurons, while glial paradigm put more emphasize to glial cells. Glioblastoma, one of the most common brain tumors, is unique due to its location, the shortness of median survival and the difficulty of efficient uptake in target tissue. Drug resistance mechanisms observed in the chemotherapy of glioblastoma are quite similar to the ones of other tumor types. These mechanisms can be investigated under two main groups: one is decreasing the sensitivity of tumor cells to chemotherapeutic agents (decreasing of drug uptake into cell by blood brain barrier and membrane transport proteins) and the other one is reducing the efficient concentration of the drug in target tissue (variabilities in detoxification proteins and hypoxia in the tumor microenvironment). Moreover, activation of oncogenes and abnormalities of expression of Bcl-2 protein family members are mediating players in the development of drug resistance in glioblastoma. In this review, the possible drug resistance mechanisms in glioblastoma were described in the light of recent literature by using systemic and integrative perspective

Özet

Merkezi sinir sisteminin gerek yapı ve fonksiyonunu gerekse patolojisini hücresel düzeyde anlamada nöronal ve glial paradigma olmak üzere iki yaklaşım öne çıkmaktadır. Nöronal paradigma nöronları, glial paradigma ise glia hücrelerini vurgulayarak patolojiyi açıklamakta ve anlamlandırmaktadır. Beyin tümörlerinin en yaygın türlerinden biri olan glioblastoma, konumu, sağ kalım süresinin kısalığı ve ilacın hedef dokuya ulaşabilirliğinin zorluğu noktalarından özgün bir tümördür. Glioblastomalarda kemoterapötik tedavi- de gözlenen ilaç direnci, diğer tümörlerde gözlenen direnç mekanizmalarıyla uyumludur. Bu direnç mekanizmaları, tümör hücreleri- nin ilaca hassasiyetini azaltan (kan beyin bariyeri ve membran transport proteinlerine bağlı olarak hücre içine ilaç girişinin azalması, DNA tamir sistemlerindeki adaptif cevap ve hedef molekülün ilaca bağlanma etkinliğinin azaltılması) ve ilaçların hedef dokudaki et- kin konsantrasyonunu azaltan mekanizmalar (detoksifikasyonda rol alan proteinlerdeki değişimler, tümör mikroçevresinde meydana gelen hipoksik bölgeler) olmak üzere iki alt başlıkta incelenebilir. Ayrıca, onkogenlerin aktivasyonu ve apoptozisle ilişkili Bcl-2 ailesi proteinlerinin ifadesindeki düzensizliklerin de ilaç direncinin ortaya çıkışında rol aldığı bilinmektedir. Bu derlemede glioblastoma tümörlerinde görülen çoklu ilaç direncinin olası mekanizmalarını güncel literatür ışığında tanımlanarak sistemik ve bütüncül bir bakış açısı ortaya konulmaya çalışılmıştır

🔖

Cite This Article

BOZKURT, E., İLHAN, H. A., UZUNOĞLU, S. (2013). Multiple drug resistance in glioblastoma. Genel Tıp Dergisi, Cilt: 23 - Sayı: 4, 133–143. https://ajindex.com/articles/202420

References (14)

  1. Weaver J. A new look at ''filler cells'' in the brain reveals their role in learning. PLoS Biol 2012;10:e1001263. Verkhratsky A and Butt A. Introduction to Glia, in Glial Neuro- biology: A Textbook. 1st ed. Chichester, UK, John Wiley & Sons Ltd, 96-121.
  2. Aggarwal S, Yurlova L, Simons M. Central nervous system myelin: structure, synthesis and assembly. Trends Cell Biol 2011;21:585- 93. Harry GJ, Kraft AD. Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology. 2012;33:191-206.
  3. Sevc J, Daxnerová Z, Ha?ová V, et al. Novel Jiangs on the origin of ependymal cells in the ventricular zone of the rat spinal cord. Acta Histochem 2011;113:156-62.
  4. Jiang Y, Uhrbom L. On the origin of glioma. Ups J Med Sci 2012;117:113-121.
  5. Herrup K, Yang Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 2007;8:368-378.
  6. Nagane M, Huang HJ, Cavenee WK. Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma. Drug Resist Updat 1999;2:30-37.
  7. Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 2012;64:640-665.
  8. Pitz MW, Desai A, Grossman SA, et al. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 2011;104:629-38.
  9. Haar CP, Hebbar P, Wallace GC, et al. Drug resistance in glioblas- toma: a mini review. Neurochem Res 2012;37:1192-200. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol Ther 2010;125:118-27.
  10. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essen- tials. Lancet Oncol 2002;3:397-406.
  11. Beaulieu E, Demeule M, Ghitescu L, et al. P-glycoprotein is strong- ly expressed in the luminal membranes of the endothelium of blo- od vessels in the brain. Biochem J 1997;326:539-44.
  12. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistan- ce gene (P-glycoprotein) is expressed by endothelial cells at blo- od-brain barrier sites. Proc Natl Acad Sci USA. 1989;86:695-8. Goldman B. Multidrug resistance: can new drugs help chemothe- rapy score against cancer? J Natl Cancer Inst 2003;95:255-7.
  13. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cas- sette (ABC) transporter superfamily. J Lipid Res 2001;42:1007-17.
  14. Vries NA, Buckle T, Zhao J, et al. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 2012;30:443-